Review article · 2012 · Open access

Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics

Alicia Ruelaz Maher, George H. Theodore

Journal of Managed Care Pharmacy, 18(5 Supp B), 1–20 · Published 1 June 2012 · DOI 10.18553/jmcp.2012.18.s5-b.1

Open PDFView at the publisherCite this paper

In brief

“Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics” is a 2012 review article by Alicia Ruelaz Maher and George H. Theodore, published in Journal of Managed Care Pharmacy. OpenAlex counts 187 citations as of 20 November 2026, which puts it in the top 5% of works published in 2012 by citations. It is open access: the full text is free to read at Journal of Managed Care Pharmacy.

Citations
187
Most cited in
2017 (16)
Field-weighted impact
2.48
References
48
Authors
2

Abstract

BACKGROUND: Conventional and atypical antipsychotic medications are approved by the FDA for treatment of schizophrenia and bipolar disorder. Over many decades, the widespread use of conventional antipsychotics produced various side effects requiring additional medications, such as the atypical antipsychotics. Beginning in 2006, 9 atypical antipsychotic drugs have been approved by the FDA for indications that were previously off-label uses: aripiprazole (as augmentation for major depressive disorder [MDD] and for autism spectrum disorders), asenapine, clozapine, iloperidone, olanzapine (in combination with fluoxetine for MDD and bipolar depression), paliperidone, quetiapine (quetiapine and quetiapine XR [extended release] as monotherapy in bipolar depression and quetiapine XR as augmentation for MDD), risperidone (for autism spectrum disorders), and ziprasidone. In 2006, the Agency for Healthcare Research and Quality (AHRQ) published a systematic review on the comparative effectiveness of off-label uses of atypical antipsychotics. Since that time, numerous studies have been published evaluating these therapies in various new off-label uses; new or increased adverse effects have been observed with off-label uses; new atypical antipsychotics have been approved; and previously off-label uses have been approved for some atypical antipsychotics. Hence, AHRQ published an updated review in September 2011 that summarized the benefits and harms of atypical antipsychotics in the treatment of attention-deficit hyperactivity disorder/attention deficit disorder (ADHD), anxiety, behavioral disturbances of dementia and severe geriatric agitation, depression, eating disorders, insomnia, obsessive-compulsive disorder (OCD), personality disorder, post-traumatic stress disorder (PTSD), substance use and dependence disorders, and Tourette's syndrome. The new report also investigated topics for which data in the previous report were found to be insufficient to make conclusions, including subpopulations (i.e., race/ethnicity, gender) that would benefit most from atypical antipsychotics, appropriate dose, and time needed to see clinical improvement. The 2011 review included the following atypical antipsychotics: aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone; no clinical trials were found for off-label use of the 3 most recently FDA-approved atypical antipsychotics (asenapine, iloperidone, and paliperidone). OBJECTIVES: To (a) familiarize health care professionals with the methods and findings from AHRQ's 2011 Comparative Effectiveness Review (CER) of off-label use of atypical antipsychotics, (b) encourage consideration of the clinical and managed care applications of the review findings, and (c) identify limitations and gaps in the existing research with respect to the benefits and risks of off-label use of atypical antipsychotics. SUMMARY: Antipsychotic medications are FDA approved for the treatment of schizophrenia and bipolar disorder. Conventional antipsychotics have been widely used for decades and spurred the development of the atypical antipsychotics. Atypical antipsychotics were produced and are now being used for patients who may have…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Maher, A. R., & Theodore, G. H. (2012). Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics. Journal of Managed Care Pharmacy, 18(5 Supp B), 1–20. https://doi.org/10.18553/jmcp.2012.18.s5-b.1

MLA 9

Maher, Alicia Ruelaz, and George H. Theodore. “Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics.” Journal of Managed Care Pharmacy, vol. 18, no. 5 Supp B, 2012, pp. 1–20. https://doi.org/10.18553/jmcp.2012.18.s5-b.1.

Chicago

Maher, Alicia Ruelaz and George H. Theodore. 2012. “Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics.” Journal of Managed Care Pharmacy 18 (5 Supp B): 1–20. https://doi.org/10.18553/jmcp.2012.18.s5-b.1.

Harvard

Maher, A. R. and Theodore, G. H. (2012) ‘Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics’, Journal of Managed Care Pharmacy, 18(5 Supp B), pp. 1–20. doi:10.18553/jmcp.2012.18.s5-b.1.

IEEE

A. R. Maher and G. H. Theodore, “Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics,” Journal of Managed Care Pharmacy, vol. 18, no. 5 Supp B, pp. 1–20, 2012, doi: 10.18553/jmcp.2012.18.s5-b.1.

BibTeX

@article{maher2012summary,
  title     = {{Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics}},
  author    = {Maher, Alicia Ruelaz and Theodore, George H.},
  journal   = {Journal of Managed Care Pharmacy},
  year      = {2012},
  volume    = {18},
  number    = {5 Supp B},
  pages     = {1--20},
  doi       = {10.18553/jmcp.2012.18.s5-b.1},
  url       = {https://doi.org/10.18553/jmcp.2012.18.s5-b.1}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20171616
20181515
201999
20201212
20211313
20221212
202399
202477
202533
202688

Its field-weighted citation impact is 2.48: it has been cited 2.48 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • atypical antipsychotics
  • off-label drug use
  • comparative effectiveness
  • aripiprazole
  • olanzapine
  • quetiapine
  • risperidone
  • ziprasidone

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Maher, A. R., & Theodore, G. H. (2012). Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics. Journal of Managed Care Pharmacy, 18(5 Supp B), 1–20. https://doi.org/10.18553/jmcp.2012.18.s5-b.1

How many times has this paper been cited?

187 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal of Managed Care Pharmacy: sign in and open the PDF from this page.

Who wrote this paper?

Alicia Ruelaz Maher, George H. Theodore.

What is the DOI of this paper?

10.18553/jmcp.2012.18.s5-b.1, permanently at https://doi.org/10.18553/jmcp.2012.18.s5-b.1. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.